Germany Added 2.5 Million Women to Mammography Screening While Reopening Skin Cancer Screening After a Proposal to Suspend It
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
Germany is widening cancer screening where the evidence is settled and reopening it where cost is the question.
The injection keeps hospital claims paid for two months. It does not change the arithmetic that created the gap.
Three routes to patients in four days. In a market that pays out of pocket, not one announcement carries a price.
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Seven of 19 applicant states have signed. CMS itself tells them to check whether its international price beats the rebates they already have.
One of the four Phase 3 studies is a safety-only switch from emicizumab. The commercial target was the incumbent, not the untreated.
The clinical case was settled before the regulatory one. Clinicians held an NCCN recommendation with no lawful product to act on it.
Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.
The lane determines the timeline, and it is set long before you file. Model the Korean queue, not the approval date.